Monday, 30 January 2017

Radiation Detection Monitoring and Safety Market Development and Demand Forecast to 2020

Radiation detection (also known as radiological detection) refers to the safety of the environment and people from harmful effects of ionizing radiation, which covers electromagnetic radiation and particle radiation.

Based on the end user industries, the global radiation detection monitoring and safety market can be broadly classified as nuclear power plants, homeland security & defense, and manufacturing industry. Further, each of the above-mentioned market segments pertaining to radiation detection, monitoring & safety market could be further segmented on the basis of composition: gas-filled detectors, and scintillators. On the basis of different product type, the radiation detection, monitoring & safety market can be classified as personal dosimeters, area process monitors, environment radiation monitors, surface contamination monitors and radioactive material monitors. As per the product use of radiation safety, the market can be further categorized into full-body accessories, hand safety accessories, face safety accessories and others. Geiger Mueller gas-filled detectors have accounted for the largest market share in 2014, which pertains to the manufacturing industry and nuclear power plant gas-filled detectors market, attributed to their portability, cost-effectiveness, and durability. Scintillators gas-filled detectors have accounted for the largest segment in homeland security and defense industry gas-filled detectors market in 2014, owing to their capability of detecting lowest levels of radiation.

Explore more about “global radiation detection monitoring and safety market” at: https://www.psmarketresearch.com/market-analysis/radiation-detection-monitoring-and-safety-market

The increased level of safety and radiation threat and rising government attention on it owing to the recent Fukushima disaster, is driving the growth of radiation detection, monitoring, and safety market. The advanced technical improvement in terms of design and efficiency is also the major factors behind their widespread acceptance in various industries. Moreover, the development of new nuclear power plants in Asia-Pacific region is also boosting the radiation detection, monitoring, and safety market in this region.


North America was the largest market for radiation detection, monitoring, and safety in 2014. The market dominance of North America was attributed to its wide nuclear power plants along with, nuclear weapon research, development and storage center. Moreover the stiffer regulation towards radiation detection, monitoring, and safety in the region has also contributed to market growth. Asia-Pacific market for the radiation detection, monitoring, and safety market is growing at a fast pace, attributed to the ongoing expansion in the nuclear power production capacity in developing countries. China, India, and Indonesia have passed many new proposals for their capacity expansion, which is expected to boost up radiation detection, monitoring, and safety market in the coming years.


Some of the major players operating in the global radiation detection monitoring & safety market include, Ametek, Inc., Atomtex SPE, Arktis Radiation Detectors, Ltd., Canberra Industries, Inc., Comecer S.P.A, Centronic Limited, Fuji Electric Co., Ltd., General Atomics Electronics Systems, Inc., General Electric Measurement and Control (GE-MCS) , Lab Impex Systems, Ltd. (Acquired By Ultra Electronics), LND, Inc., Landauer, Inc., Ludlum Measurements, Inc., Radiation Monitoring Devices, Inc., Redlen Technologies, Inc., RAE Systems, Inc., S.E. International, Inc. , Thermo Fisher Scientific, Inc., and Smiths Detection Group, Ltd.

Acute Ischemic Stroke Diagnosis and Treatment Market Development, Growth and Demand Forecast to 2020

Acute ischemic stroke refers to a sudden loss of certain brain function owing to uneven or lack of blood to the brain. Acute ischemic functions are mainly triggered by atherosclerosis plaques blocking blood vessels, blood clots locking the blood distribution to or from arteries nourishing the brain, or narrowing of blood vessels of the brain. Acute ischemic stroke is one of the major causes of permanent disability in the patients. It is also the third largest reason of death worldwide. Acute ischemic stroke can affect persons of all age groups. However, acute ischemic stroke most commonly affects the individuals, who are above 60 years, the risk of acute ischemic stroke increases with age. Driven by the technical advancement in diagnosis, the acute ischemic stroke diagnosis and treatment demand is expected to experience an escalating demand in coming years.


The advancements in the surgical devices technology, in addition with the rising occurrence of acute ischemia stroke cases among the patients are some of the dominant driving factor for the surgery in acute stroke treatment. Some of the other factors driving the market include, aging population mainly in the developed countries of Europe and North America. The development of the effective medication in the treatment of ischemic stroke is accepted to hinder the acceptance of expensive surgery in the ischemic stroke diagnosis market. The development of desmoteplase, a novel next-generation thrombolytic, is one of the major advancement of in the treatment technology of acute ischemic stroke. It provides extended therapeutic time compared to most of the other treatment procedure. Moreover, with the increasing impact of telemedicine and e-prescription and e-medical adherence the acute ischemic stroke diagnosis and treatment market is expected to flourish at a healthy rate during the forecast period.


The major hindrance in the development of acute ischemic stroke diagnosis and treatment market is in the clinical trial, which include long testing of drug after stroke onset, in addition to insufficient selection of patients for the trials.

Based on the various diagnosis and treatment the global acute ischemic stroke diagnosis and treatment market can be segmented as computed tomography, magnetic resonance imaging, ultrasound, cerebral angiography, nuclear imaging, and others. Based on the various surgery types the global acute ischemic stroke diagnosis and treatment market can be broadly segmented as carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy.


Some of the leading players operating in global acute ischemic stroke diagnosis and treatment  market include, Abbott Laboratories, Covidien plc, Johnson & Johnson (Cordis Corporation), Penumbra, Inc., Philips Healthcare, GE Healthcare, Hitachi, Ltd., Siemens Healthcare, and Stryker Corporation (Concentric Medical, Inc.)

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication.  Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com

Sunday, 22 January 2017

Clinical Nutrition Market, Trends, Size, Development, Growth and Forecast to 2022 by P&S Market Research


The global clinical nutrition market was valued at $39,339.4 million in 2015, and it is expected to grow at a CAGR of 5.4% during 2016 - 2022. The factors driving the growth of the global market include increasing geriatric population, high birth rate and high number of premature birth, surge in the number of victims of malnutrition receiving treatment, surging incidence of lifestyle associated disease, and increasing incidence of cancer and central nervous system diseases. Malnutrition is a widespread problem, affecting the lives of millions of people globally. It is a condition that occurs due to deficiency of essential nutrients in the body. In 2010, around 40% of all hospital patients globally were malnourished. Clinical nutrition is the most efficient way to treat malnutrition and helps in avoiding associated costs. In Europe, around one-third of all hospital patients were malnourished in 2012. The increase in the number of victims of malnutrition globally, is expected to result in an increased usage of healthcare resource due to the longer stays in hospitals. As per an article of 2012, the malnutrition cost European government up to USD 237.0 billion a year; while the clinical nutrition accounted for about 2.5% of the cost involved with malnutrition.


The increasing incidence of cancer and central nervous system (CNS) diseases is driving the growth of the global enteral nutrition market. Enteral nutrition products are considered to be one of the best alternatives during the treatment of cancer and CNS diseases, to avoid nutrition deficiency in human body, for optimal functioning of various organs. Cancer can change the metabolism of nutrient uptake in patient’s body, therefore they require good nutrition. Cancer may lead to malnutrition and weight loss; therefore, patients are required continuous nutrient feeding. Enteral nutrition is one of the best solutions to the problem. According to the WHO, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 globally. The organization also reported that 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions.



Some of the major players operating in the global clinical nutrition market include Baxter International Inc., Abbott Laboratories, B. Braun Melsungen AG, Nestlé S.A., Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, and Perrigo Company Plc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: 
https://www.psmarketresearch.com

Friday, 20 January 2017

Antibody Drug Conjugates Therapeutics Market, Trends, Size, Share, Growth and Forecast to 2022

The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.
Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market

The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.

ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.
A large number of pharmaceutical companies are focusing towards research and development of ADCs. However, certain factors such as unknown etiology, complex pathophysiology and high treatment cost of cancer are expected to hamper the growth of the global market during the forecast period.

Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.         

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive
– Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: 
https://www.psmarketresearch.com

Idiopathic Pulmonary Fibrosis Therapeutics Market, Trends, Size, Share, Growth and Forecast to 2022 by P&S Market Research

The global idiopathic pulmonary fibrosis therapeutics market is expected to witness significant growth due to current unmet medical need of pulmonary fibrosis, scarcity of the permanent treatment of the disease, increasing incidence among population across the globe, and high demand for safe and effective medication. The regulatory bodies are supporting the idiopathic pulmonary fibrosis market by providing designations and grants for speeding up the drug development process. In March 2015, Lebrikizumab, a Genentech’s humanized monoclonal antibody drug, received Orphan Drug Designation by U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis.

The pipeline of idiopathic pulmonary fibrosis is rich, with more than 50 drugs. The pharmaceutical companies are actively involved in the research and development of drug for idiopathic pulmonary fibrosis. Asahi Kasei Pharma Corporation has Thrombomodulin Alfa drug in its Phase III clinical trial for idiopathic pulmonary fibrosis. The drug is already marketed in Japan, under the name of Recomodulin for the treatment of disseminated intravascular coagulation.

Idiopathic pulmonary fibrosis is defined as a chronic, gradually increasing lung disease of unknown cause. The disease primarily involves the interstitium (the tissue and space around the air sacs of the lungs) and it does not directly affect the airways or blood vessels. The lung damage caused by pulmonary fibrosis cannot be repaired; however, medications and therapies can help to ease symptoms and improve quality of life. Management and surgery are the only options to prevent further complications of idiopathic pulmonary fibrosis. The damage caused from the lung scarring cannot be reversed.

Geographically, North America is expected to be the largest market for idiopathic pulmonary fibrosis owing to the large number of research and development activities, high healthcare expenditure, and high incidence of the disease. The U.S. contributed largest revenue to the North American idiopathic pulmonary fibrosis market and it is expected to remain the largest market globally, during the forecast period.


Some of the key players operating in the global idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Merck & Co., Inc., Promedior, Inc., Sanofi, ProMetic Life Sciences Inc., Kadmon Holdings, Inc., MediciNova, Inc., GlaxoSmithKline plc, Biogen Inc., and Celgene Corporation.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive
– Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: 
https://www.psmarketresearch.com

Wednesday, 11 January 2017

Global Denim Jeans Market, Analysis, Development, Growth and Demand Forecast to 2020

The evergreen image of denim jeans is the key growth driver for its market.  The mass market of denim jeans accounted for the largest segment in the global denim jeans market. North America is the largest market followed by Europe. The market in Asia-Pacific is growing at the fastest pace, owing to increased rate of urbanization and increasing disposable income of the consumers.


There are several types of jeans based on the type of tailoring, and fashion works done onto them. They include skinny, tapered, slim, straight, boot cut, cigarette bottom, narrow bottom, low waist, and anti-fit. Asia-Pacific accounted for the largest denim fabric production. The economic slowdown in Europe has significantly impacted the growth of the market in the region. The consumers of standard and premium denim jeans started to trade down mass market jeans, which significantly affected the value sales in the market. The jeans manufacturer have started to replace cotton used in them with polyester, in an attempt to further lower the price of mass market jeans.


China, Turkey, Brazil, Vietnam, India, and Pakistan are the countries that are expected to witness strong growth in the global market during the forecast period. The lower labor cost in Vietnam is expected to make it one of the most prospective destinations for denim jeans production in Asia-Pacific. The growth rate of the denim jeans market in the countries of North America and Europe is expected to be moderate. The increasing population in China and India, along with up surging middle class population is presenting favorable growth  opportunity for the jeans market in Asia-Pacific. The U.S. imports large volume of denim jeans from Mexico and China. The denim jeans production capacity of Brazil is increasing at a swift pace.  Italy is the largest denim jeans producer in Europe; however it has been increasing the sourcing of fabric from Turkey and North Africa.

Based on consumer type, the global denim jeans market is dominated by women, followed by men. The children’s segment is growing at a fast pace, due to the increasing sense of fashion among the consumer type. The larger share of women consumers is due to their freedom to wear denim jeans on all the weekdays in corporates.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com